Clinical pharmacology of alendronate sodium
Osteoporosis International1993Vol. 3(S3), pp. 13–16
Citations Over TimeTop 11% of 1993 papers
Related Papers
- → Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis(2001)189 cited
- → Differential Action of the Bisphosphonates (3-Amino-1-Hydroxypropylidene)-1,1-Bisphosphonate (APD) and Disodium Dichloromethylidene Bisphosphonate (Cl2MDP) on Rat Macrophage-mediated Bone Resorption In Vitro(1982)123 cited
- → Bisphosphonates in the Management of Postmenopausal Osteoporosis(2001)17 cited
- → Disodium 1-hydroxy-3-(1-pyrrolidinyl)-propylidene-1,1-bisphosphonate (EB-1053) is a potent inhibitor of bone resorption in vitro and in vivo(1992)25 cited
- → Bisphosphonates can Reduce Osteoclastic Bone Resorption by Two Different Mechanisms(1986)15 cited